We are live on ! Find out more
NMTR

9 Meters Biopharma
NMTR

Delisted

NMTR was delisted on the 25th of July, 2023.

Back to rankings

74 hedge funds and large institutions have $10.4M invested in 9 Meters Biopharma in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,309% more call options, than puts

Call options by funds: $324K | Put options by funds: $23K

19% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 16

16% less funds holding

Funds holding: 88 → 74 (-14)

20% less capital invested

Capital invested by funds: $13M → $10.4M (-$2.6M)

50% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 26

Holders
74
Holders Change
-14
Holders Change %
-15.91%
% of All Funds
1.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
19
Reduced
16
Closed
26
Calls
$324K
Puts
$23K
Net Calls
+$301K
Net Calls Change
-$121K

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$466K
2
Renaissance Technologies
Renaissance Technologies
New York
+$296K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$262K
4
Two Sigma Investments
Two Sigma Investments
New York
+$210K
5
RCM
Requisite Capital Management
Texas
+$74.3K

Top Sellers

Rank Fund Capital Flow
1
CWM
Curi Wealth Management
North Carolina
-$498K
2
GTC
Ghost Tree Capital
New York
-$469K
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$321K
4
Millennium Management
Millennium Management
New York
-$221K
5
YIH
Y-Intercept (HK)
Hong Kong
-$48K
Name Holding Trade Value Shares
Change 		Change in
Stake
KIA
51
KCM Investment Advisors
California
$3K – – –
IWM
52
IHT Wealth Management
Illinois
$3K +$496 +100 +20%
Two Sigma Advisers
53
Two Sigma Advisers
New York
$3K +$3.22K +650 New
HF
54
HRT Financial
New York
$3K +$3.49K +704 New
IFG
55
Independent Financial Group
California
$2.15K – – –
CIC
56
Carnegie Investment Counsel
Ohio
$2K – – –
GA
57
Gateway Advisory
New Jersey
$2K – – –
JSW
58
Journey Strategic Wealth
New Jersey
$2K – – –
SCP
59
Sandhill Capital Partners
New York
$2K – – –
TAM
60
Tocqueville Asset Management
New York
$2K – – –
WS
61
Wedbush Securities
California
$2K – – –
SXL
62
Summit X LLC
Missouri
$1K -$991 -200 -24%
BCMLT
63
Beacon Capital Management LLC (Tennessee)
Tennessee
$1K – – –
MA
64
MCF Advisors
Kentucky
$1K – – –
PNC Financial Services Group
65
PNC Financial Services Group
Pennsylvania
$1K – – –
PA
66
PSI Advisors
Florida
$1K – – –
Royal Bank of Canada
67
Royal Bank of Canada
Ontario, Canada
$1K +$119 +24 +15%
WFA
68
Wipfli Financial Advisors
Wisconsin
$1K +$1.11K +225 New
Bank of Montreal
69
Bank of Montreal
Ontario, Canada
$19 +$3.92K +791 +24%
O
70
OrbiMed
New York
– -$2.22K -425,286 Closed
GTC
71
Ghost Tree Capital
New York
– -$469K -90,000 Closed
YIH
72
Y-Intercept (HK)
Hong Kong
– -$48K -9,216 Closed
SSA
73
Schonfeld Strategic Advisors
New York
– -$29K -5,480 Closed
LP
74
LMR Partners
United Kingdom
– -$28K -5,384 Closed
AI
75
Atom Investors
Texas
– -$27K -5,117 Closed
1 2
3
4

NMTR Hedge Fund Activity: Q3 2022 in Review

74 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q3 2022, worth a combined $10.4M — down 20% from $13M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of NMTR and 13 opened new positions — a net loss of 13 holders — while 16 trimmed existing stakes and 19 added.

The largest buyer was GSA Capital Partners, adding an estimated $466K. The largest seller was Curi Wealth Management, cutting an estimated $498K.

  • 74 institutional investors held 9 Meters Biopharma (NMTR) as of Q3 2022, down from 88 in Q2 2022.
  • Funds reported $10.4M of 9 Meters Biopharma stock for Q3 2022, down 20% quarter-over-quarter.
  • 13 funds opened new 9 Meters Biopharma positions in Q3 2022 and 26 closed out, a net change of -13 holders.
  • The largest 9 Meters Biopharma buyer in Q3 2022 was GSA Capital Partners, an estimated $466K added.
  • The largest 9 Meters Biopharma seller in Q3 2022 was Curi Wealth Management, an estimated $498K sold.

Based on aggregated 13F filings for Q3 2022.